Pricing Log in Create free account
Friday 6 November 2026 Export QTRX’s income statement to Excel — free account

Quanterix Corporation

QTRX Healthcare Medical Devices

Quanterix Corporation’s revenue for fiscal 2025 (year ended December 2025) was $138.9 million, up 1.07% from fiscal 2024.

Revenue
+34.4%
EPS
−35.1%
Free cash flow
+18.9%

Quarter to June 2026, against a year earlier

2.86 0.10 +3.62%
Market cap
$130.5M
P/E
0.0×
Fwd P/E
−1.5×
Dividend yield
—
F-score
3/9
Altman Z
−0.87
Beneish M
−0.69
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.30
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — 1 — — 1 — — —
Sell — — — — — — — — — — — —
Insider Ownership 11.48%

Capital & Financial Ratios $m

Size
Market Cap 130.53
Revenue ttm 153.41
Net income ttm (123.11)
Free cash flow ttm (81.68)
Net debt Q (93.53)
Valuation
P/E 0.00
Forward P/E (1.49) (negative: loss-making)
Price / sales 0.85
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.55
Financial health
Current ratio Q 3.40 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 3.32
Growth
Revenue growth Q +34.44% (above 0%: growing)
Operating income growth Q −33.24% (below 0%: shrinking)
EPS, this year +10.76%
EPS, next year A +44.80% (at or above 15%: strong)
Revenue, next year A +3.24%
EPS, past 5 yrs —
EPS, next 5 yrs A +25.85% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.3×, against a ten-year median of 5.1×; over the ten years it ranged from −0.3× in 2025 to 24.2× in 2021.
P/S against its own 10 years 1.03%
10-year low 10-year high
P/B against its own 10 years 2.47%
10-year low 10-year high
EV/Sales against its own 10 years 4.55%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 321 289 118 94
Receivables 25 32 30 22
Inventory 26 33 55 48
Other — — — —
382 364 212 171
2023 2024 2025 Q'26
Payables 5 7 14 9
ST’ Debt — — — —
Other — — — —
39 42 75 50

Compound Annual Growth %

10y 5y 3y
Sales 27.56% 9.97% 9.59%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 7.49% (6.16%)

Earnings Trends EPS, adjusted, against the consensus

Q1 FY26 Estimate −0.31 Actual −0.39

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY25 −0.41 −0.47 Miss by 0.06
Q3 FY25 −0.23 −0.36 Miss by 0.13
Q4 FY25 −0.27 −0.38 Miss by 0.11
Q1 FY26 −0.31 −0.39 Miss by 0.08

EPS $

Mar Jun Sep Dec Year
’26 (0.37) (1.04) — — —
’25 (0.53) (0.77) (0.73) (0.49) (2.51)
’24 (0.26) (0.19) (0.22) (0.30) (1.00)
’23 (0.16) (0.16) (0.21) (0.23) (0.75)
’22 (0.49) (0.67) (0.95) (0.50) (2.61)
’21 (0.29) (0.33) (0.43) (0.55) (1.60)
’20 (0.39) (0.42) 0.07 (0.31) (1.10)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 36 33 — — —
’25 30 24 40 44 139
’24 32 34 36 35 137
’23 28 31 32 32 122
’22 30 24 27 26 106
’21 27 25 28 30 111
’20 16 13 31 26 86
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (18) (5) — — —
’25 (14) (6) (41) (16) (77)
’24 (20) (5) (6) (4) (35)
’23 (10) 1 (4) (6) (19)
’22 (22) (8) (15) (4) (49)
’21 (14) (10) (14) (10) (48)
’20 (13) (7) (7) 5 (23)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (18) (5) — — —
’25 (15) (6) (42) (16) (80)
’24 (21) (7) (7) (5) (39)
’23 (10) 0 (5) (8) (23)
’22 (23) (13) (18) (6) (60)
’21 (14) (17) (18) (13) (61)
’20 (14) (8) (8) 3 (27)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 18 23 38 57 86 111 106 122 137 139 153 +25.8% 143 158 181 +9.2%
Gross margin, % 44.06 43.66 47.69 47.30 55.78 58.59 42.99 60.66 60.47 46.77 44.56 +2.7 pt
EBT (23) (27) (32) (41) (32) (56) (99) (28) (38) (112) (125) +19.2%
EBT margin, % (131.78) (118.12) (83.73) (72.24) (36.94) (50.28) (94.21) (22.58) (27.72) (80.83) (81.68) +51.0 pt
Net income (23) (27) (32) (41) (32) (56) (100) (28) (39) (107) (123) +18.5%
Per share, $
Per share, $ Revenue 8.21 6.09 1.71 2.26 2.92 3.07 2.85 3.26 3.58 3.26 3.25 (9.8%)
Earnings (12.89) (8.30) (1.43) (1.63) (1.10) (1.60) (2.61) (0.75) (1.00) (2.51) (2.63) (16.6%)
Cash flow (8.28) (5.88) (1.31) (1.04) (0.79) (1.32) (1.31) (0.50) (0.92) (1.81) (1.72) (15.5%)
Capex (0.25) (0.30) (0.07) (0.43) (0.13) (0.38) (0.31) (0.10) (0.09) (0.06) (0.02) (14.3%)
Free cash flow (8.52) (6.19) (1.37) (1.48) (0.92) (1.70) (1.63) (0.60) (1.00) (1.87) (1.73) (15.5%)
Book value 6.29 17.53 1.87 5.13 6.97 12.25 9.68 9.31 8.60 6.94 5.03 +1.1%
Shares, m 2 4 22 25 30 36 37 38 38 43 46 +39.4%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 0.00 6.61 10.70 10.45 15.93 13.81 4.51 8.34 2.97 1.95 0.85 7.5
P/B 0.00 2.30 9.81 4.61 6.68 3.46 1.33 2.92 1.24 0.92 0.55 3.3
EV/Sales 0.00 3.54 9.93 8.66 14.17 10.42 1.71 6.04 1.16 1.12 0.25 5.7
EV/FCF (0.65) (3.48) (12.36) (13.27) (44.84) (18.80) (2.99) (32.60) (4.13) (1.95) (0.47) (13.5)
Cash, $m
Cash, $m Operating cash flow (18) (22) (29) (26) (23) (48) (49) (19) (35) (77) (81) +17.8%
Capex (1) (1) (2) (11) (4) (14) (12) (4) (3) (3) (1) +19.5%
Free cash flow (18) (23) (30) (37) (27) (61) (60) (23) (39) (80) (82) +17.8%
Balance, $m
Balance, $m Working capital 24 70 41 113 180 412 350 343 322 137 121 +21.2%
Net debt (19) (70) (37) (101) (174) (396) (339) (321) (289) (118) (94) +22.2%
Shareholders’ equity 13 66 41 129 206 441 358 350 330 296 237 +40.9%
Returns, %
Returns, % ROA (124.22) (48.39) (39.57) (34.35) (14.30) (14.38) (21.30) (6.58) (9.23) (25.97) (35.41) +98.3 pt
ROIC 0.00 0.00 (462.99) (95.71) (61.28) (79.41) (339.54) (100.39) (80.37) (44.21) (66.50) (44.2) pt
ROE 27.11 126.67 (58.98) (48.07) (18.84) (17.17) (24.93) (8.01) (11.33) (34.25) (46.48) (61.4) pt
People
People Employees 122 126 177 248 314 460 125 441 471 450 — +15.6%
Revenue/emp, $m 0.14 0.18 0.21 0.23 0.28 0.24 0.84 0.28 0.29 0.31 — +8.8%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Quanterix Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RXST RxSight, Inc. $190.4M — (loss-making) — (loss-making) −18.97% (below 0%: shrinking) n/m +2,591.06% (above 0%: growing) 73.62% (75.32%) Compare
STIM Neuronetics, Inc. $185.2M — (loss-making) — (loss-making) +12.51% (above 0%: growing) n/m +237.71% (above 0%: growing) 52.17% 1.29% Compare
INGN Inogen, Inc $179.7M — (loss-making) — (loss-making) +3.04% (above 0%: growing) n/m −51.15% (below 0%: shrinking) 45.51% (5.36%) Compare
MXCT MaxCyte, Inc. $135.2M — (loss-making) — (loss-making) −14.53% (below 0%: shrinking) n/m +54.74% (above 0%: growing) 76.96% (140.72%) Compare
QTRX Quanterix Corporation $130.5M — (loss-making) — (loss-making) +34.44% (above 0%: growing) n/m +18.92% (above 0%: growing) 38.52% (150.22%)
APYX Apyx Medical Corporation $128.9M — (loss-making) — (loss-making) +8.95% (above 0%: growing) n/m +53.17% (above 0%: growing) 64.16% (4.07%) Compare
OWLT Owlet, Inc. $123.9M — (loss-making) — (loss-making) +29.94% (above 0%: growing) n/m +55.74% (above 0%: growing) 64.44% 5.14% Compare
LUNG Pulmonx Corporation $111.5M — (loss-making) — (loss-making) +6.20% (above 0%: growing) n/m +61.33% (above 0%: growing) 76.19% (32.80%) Compare
CATX Perspective Therapeutics, Inc. $90.0M — (loss-making) — (loss-making) −72.07% (below 0%: shrinking) n/m −66.09% (below 0%: shrinking) 100.00% (36,120.99%) Compare
Median of peers $132.1M — — +4.62% — +55.24% 69.03% (19.08%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 24 April 2026

Ownership

Directors and executive officers, together 1.50%
Entities affiliated with Ameriprise Financial, Inc. 10.60%
Entities affiliated with Telegraph Hill Partners, L.P. 5.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Quanterix Corporation (QTRX) Latest News

7 Oct

Impact 4 · · PR Newswire
Impact 4 · · PR Newswire
Impact 4 · · Business Wire

25 Sep

Impact 4 · · Business Wire

17 Aug

Impact 4 · · The Motley Fool transcript

16 Aug

Impact 4 · · MarketBeat

12 Aug

Impact 3 ·

10 Aug

Impact 4 · transcript
Impact 4 · · InvestorsHub
Impact 3 · · MarketBeat transcript

14 Jul

Impact 4 ·

9 May

Impact 4 · · Simply Wall St.

7 May

Impact 4 · · The Motley Fool transcript
Impact 3 · · Moby
Impact 3 · · MarketBeat

6 May

Impact 4 ·
Impact 3 · · Zacks
Impact 3 · · Business Wire

2 May

Impact 4 · · Simply Wall St.

17 Apr

Impact 4 · · Business Wire

15 Apr

Impact 4 ·

3 Mar

Impact 4 · · The Motley Fool transcript
Impact 4 · · Moby
Impact 4 · · GuruFocus.com

2 Mar

Impact 4 · · MarketBeat
Impact 4 · · Business Wire
Impact 4 · · Business Wire
Impact 3 · · Zacks

14 Feb

Impact 4 · · Simply Wall St.

4 Feb

Impact 4 · · Zacks
stockrow.com/QTRX · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com